Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction

Inclusion Criteria: * Age ≥ 18 years old * Chest pain or equivalent lasting \> 20 minutes * ST elevation myocardial infarction scheduled for primary PCI * Signed written informed consent Exclusion Criteria: * Previous myocardial infarction * Previous percutaneous or surgical myocardial revascularization * Ongoing treatment with any statin or ezetimibe * History of congestive heart failure * Cardiogenic shock at presentation * Known Pregnancy * Women of Childbearing Age * Known major active infection or major hematologic, renal, hepatic, or endocrine dysfunction * Malignancy (except non-melanoma skin cancer, cervical in situ carcinoma, breast ductal carcinoma in situ, stage 1 prostate carcinoma) within the last 10 years * Patients with hypersensitivity to the active substance (evolocumab) or to any of its excipients * Inability to attend the scheduled clinical evaluation and laboratory tests * Inability to undergo the pharmacological treatment or other procedures of the study * Currently enrolled in another investigational drug study, or \< 30 days/\<5 half-life since ending another investigational drug study(s).